Received Feb 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | LA |
Nausea; Dizziness; Pain; Allergy; This non-serious case was reported by a consumer via call center representative and described the occurrence of nausea in a 53-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 30-JAN-2025, the patient received the 2nd dose of Shingrix (left arm). On an unknown date, an unknown time after receiving Shingrix, the patient experienced nausea (Verbatim: Nausea), dizziness (Verbatim: Dizziness), pain (Verbatim: Pain) and allergy (Verbatim: Allergy). The outcome of the nausea and dizziness were not resolved and the outcome of the pain and allergy were unknown. It was unknown if the reporter considered the nausea, dizziness, pain and allergy to be related to Shingrix. It was unknown if the company considered the nausea, dizziness, pain and allergy to be related to Shingrix. Additional Information: GSK Receipt Date: 04-FEB-2025 The patient self-reported this case. The patient received her second dose of Shingrix and was still having dizziness and nausea today (on the reporting day). It was not provided when the dizziness or nausea started and she read to take Tylenol and Advil and that these did not help with pain involved with the shot or after effects (no further information provided). It was not clear if the patient took either Tylenol or Advil (unknown product information). The patient reported that her physician told her to come in to note an allergy in her chart after receiving the second dose of Shingrix, but no further information was provided about the potential allergy.